<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptorepositive, human epidermal growth factor receptor 2enegative early-stage breast cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-08-18">18 August 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Joan</forename><surname>Albanell</surname></persName>
							<email>jalbanell@hospitaldelmar.cat</email>
							<affiliation key="aff0">
								<orgName type="department">Medical Oncology</orgName>
								<orgName type="institution">Hospital del Mar</orgName>
								<address>
									<addrLine>Passeig Maritim 25-29</addrLine>
									<postCode>08003</postCode>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">CEXS Department</orgName>
								<orgName type="institution">Pompeu Fabra University</orgName>
								<address>
									<addrLine>Plac ¸a de la Merce`, 10</addrLine>
									<postCode>08002</postCode>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Cancer Research Programme</orgName>
								<orgName type="institution">Hospital del Mar Medical Research (IMIM) Institute</orgName>
								<address>
									<addrLine>Carrer del Dr. Aiguader, 88</addrLine>
									<postCode>08003</postCode>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christer</forename><surname>Svedman</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Genomic Health, Inc</orgName>
								<address>
									<addrLine>301 Penobscot Dr</addrLine>
									<postCode>94063</postCode>
									<settlement>Redwood City</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joseph</forename><surname>Gligorov</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Medical Oncology</orgName>
								<orgName type="department" key="dep2">Francilian Breast Intergroup</orgName>
								<orgName type="institution" key="instit1">APHP Tenon</orgName>
								<orgName type="institution" key="instit2">IUC-UPMC Sorbonne University</orgName>
								<orgName type="institution" key="instit3">APREC</orgName>
								<address>
									<country>Paris</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><forename type="middle">D H</forename><surname>Holt</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Breast Cancer Unit</orgName>
								<orgName type="institution">Prince Philip Hospital</orgName>
								<address>
									<addrLine>Bryngwyn Mawr Dafen Road</addrLine>
									<postCode>SA14 8QF</postCode>
									<settlement>Llanelli, Carmarthenshire</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gianfilippo</forename><surname>Bertelli</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Oncology</orgName>
								<orgName type="institution">Singleton Hospital</orgName>
								<address>
									<addrLine>Sketty Lane</addrLine>
									<postCode>SA2 8QA</postCode>
									<settlement>Sketty, Swansea</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jens-Uwe</forename><surname>Blohmer</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Gynecology with Breast Center</orgName>
								<address>
									<addrLine>Charite´platz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Charite´Hospital, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roman</forename><surname>Rouzier</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Surgical Oncology</orgName>
								<orgName type="institution">Institut Curie</orgName>
								<address>
									<addrLine>26 rue d&apos;Ulm</addrLine>
									<postCode>75248, Cedex 05</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ana</forename><surname>Lluch</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Hematology-Oncology</orgName>
								<orgName type="institution" key="instit1">Hospital Clinico</orgName>
								<orgName type="institution" key="instit2">INCLIVA</orgName>
								<orgName type="institution" key="instit3">University of Valencia</orgName>
								<address>
									<addrLine>Av. de Blasco Iba´n˜ez, 17, Vale`ncia</addrLine>
									<postCode>46010</postCode>
									<settlement>Valencia</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Eiermann</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Gynecology and Oncology</orgName>
								<orgName type="department" key="dep2">Interdisciplinary Oncology Center</orgName>
								<address>
									<addrLine>Nussbaumstr. 12</addrLine>
									<postCode>80336</postCode>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Medical Oncology Service</orgName>
								<orgName type="institution">Hospital del Mar</orgName>
								<address>
									<addrLine>Passeig Maritim 25-29</addrLine>
									<postCode>08003</postCode>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptorepositive, human epidermal growth factor receptor 2enegative early-stage breast cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-08-18">18 August 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">03369F3373F4F9E9ACBE7412D830C1FB</idno>
					<idno type="DOI">10.1016/j.ejca.2016.06.027</idno>
					<note type="submission">Received 1 March 2016; received in revised form 19 May 2016; accepted 13 June 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Adjuvant chemotherapy; Breast cancer;</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/ predictive information in oestrogen receptor positive (ERþ) early breast cancer, but access/ reimbursement has been limited in most European countries in the absence of prospective outcome data.</s><s>Recently, two large prospective studies and a real-life 5-year outcome study</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>Only a modest proportion of patients with oestrogen receptor positive (ERþ) human epidermal growth factor receptor 2 (HER2)enegative early breast cancer benefit from adjuvant chemotherapy <ref type="bibr" target="#b0">[1]</ref>.</s><s>Since currently used traditional markers are prognostic but not predictive of chemotherapy benefit, there is substantial overtreatment.</s><s>The 21-gene Recurrence Score assay (the Oncotype DX â Breast Recurrence Score Assay; Genomic Health, Inc., Redwood City, CA) is a validated prognosticator (in ERþ node-negative and nodepositive early breast cancer patients) that provides independent prognostic information to traditional measures and has been shown to predict adjuvant chemotherapy benefit when tested in patients previously included in phase III clinical trials that randomised patients to hormonal therapy (HT) alone versus chemohormonal therapy (CHT) <ref type="bibr">[1e6]</ref>.</s></p><p><s>Importantly, results from four recently published/ presented studies now confirm the available prospective retrospective validation data.</s><s>The prospective phase III TAILORx adjuvant trial demonstrated that in nodenegative hormone receptor (HR)þ HER2-negative patients (n Z 1626) with low <ref type="bibr" target="#b9">(10)</ref> Recurrence Score results treated with HT alone, distant-recurrence risk at 5 years was very low (0.7%) <ref type="bibr" target="#b6">[7]</ref>.</s><s>The prospective phase III WSG Plan B trial in patients with node-positive or highrisk node-negative HRþ HER2-negative disease showed that in this patient population too, the distant-recurrence risk is very low in patients (n Z 348) with Recurrence Score results 11 and HT alone (3-year event-free survival of 98.3%) <ref type="bibr" target="#b7">[8]</ref>.</s><s>The third study evaluated a large cohort (n Z 2028) of patients for whom treatment decisions incorporated the assay in real-life clinical practice <ref type="bibr" target="#b8">[9]</ref>.</s><s>It reported a 5-year rate of distant recurrence of 0.8% in patients with low Recurrence Score results (&lt;18) treated with HT (2% chemotherapy use), a 3.2% rate in patients with intermediate scores (18e30) (25% chemotherapy use), and a 10.6% rate in patients with high scores <ref type="bibr" target="#b30">(31)</ref> (88% chemotherapy use) <ref type="bibr" target="#b8">[9]</ref>.</s><s>The fourth study was a prospectively defined analysis of the Surveillance, Epidemiology, and End Results registry which was electronically supplemented with Recurrence Score results.</s><s>It reported survival data only and demonstrated excellent 5-year breast cancer-specific survival in &gt;21,000 node-negative HRþ HER2-negative breast cancer patients with low Recurrence Score results (99.6%) <ref type="bibr" target="#b9">[10]</ref>.</s></p><p><s>The Recurrence Score assay is incorporated in major international guidelines such as the American Society of Clinical Oncology (ASCO â ), National Comprehensive Cancer Network â (NCCN â ), European Society for Medical Oncology, and St Gallen as a tool to help estimate prognosis and the magnitude of chemotherapy benefit <ref type="bibr">[11e14]</ref>.</s></p><p><s>Despite inclusion in all major international guidelines, less than 20% of patients in Europe have access to the Recurrence Score assay through national reimbursement.</s><s>Absence of outcome data from prospective studies as well as from real-life studies in patient populations that are using the assay to guide treatment decisions has been stated as the main cause for lack of reimbursement in many countries.</s><s>Treatment recommendations in ERþ early breast cancer in European countries vary owing to different therapeutic traditions/ local guidelines.</s><s>With prospective outcome data available, an increase in access and reimbursement is likely.</s><s>Therefore, it is relevant to assess the impact of using the assay in different patient populations and countries.</s><s>Here, we performed a pooled analysis in order to generate as robust data as possible regarding the impact of the assay on adjuvant treatment recommendations in node-negative ERþ, HER2-negative breast cancer in available prospective European decision impact studies.</s><s>We evaluated the association between traditional parameters and assay-driven treatment recommendation changes and also compared treatment recommendations between study countries pre-and post-assay.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Patient population</head><p><s>The analysis included four European prospective studies finalised to date, according to the best knowledge of the authors.</s><s>These similarly designed studies investigated the impact of Recurrence Score testing on clinical decisions in France, Germany, Spain, and the United Kingdom (UK) <ref type="bibr">[15e18]</ref>.</s><s>In these studies, consecutive patients with no contraindications to chemotherapy were enrolled, adjuvant treatment recommendations of the treating physician pre-and post-Recurrence Score testing were recorded, and the treating physicians completed questionnaires regarding their confidence in their treatment recommendations before/after testing.</s></p><p><s>All patients included in the final pooled analysis (n Z 527) were node negative, ERþ, HER2 negative and underwent Recurrence Score testing as per study protocols.</s><s>Node-positive patients, patients with micrometastases, and those with no available Recurrence Score results were excluded (n Z 151) to provide a more homogeneous study population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Statistical analysis</head><p><s>Analysis of variance/chi-squared tests were used to assess continuous/categorical parameters across studies.</s><s>McNemar's test was used to assess whether the change (from pre-to post-testing) in the proportion of patients with CHT and HT recommendations was significant.</s><s>Wilcoxon signed-rank test was used to assess whether the change (from pre-to post-testing) in physicians' confidence was significant.</s></p><p><s>Using logistic regression analysis, the probability of a treatment recommendation change was modelled as a function of the Recurrence Score category (as defined by Paik et al. <ref type="bibr" target="#b1">[2]</ref>), age (&lt;55, 55 years; this cutoff value was chosen as a proxy for menopausal status), tumour size (2, &gt;2 cm; i.e.</s><s>T1 versus T2/T3), grade (IeIII), progesterone receptor (PR) status, and Ki-67 levels (&lt;20%, 20%).</s><s>Patients with missing data were excluded from the analysis.</s><s>Stepwise regression analysis was performed to determine whether interactions between the evaluated covariates and the Recurrence Score result should be included in the model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Study patients</head><p><s>The analysis included 565 patients (French study, 83; Spanish study, 107; UK study, 131; and German study, 244).</s><s>The patient populations were similar with respect to age and PR status and differed with respect to tumour size and grade (p &lt; 0.0001, both variables) (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Recurrence Score distribution</head><p><s>A wide range of Recurrence Score results was observed in the pooled cohort (Fig. <ref type="figure" target="#fig_0">1</ref>) with a median (range) of 16 (0e81) and a mean (SD) of 18.1 (10.1) (p Z 0.19 for comparison across studies).</s><s>The distribution of Recurrence Score categories differed across the studies (p Z 0.031) (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>The distribution of these Recurrence Score categories was similar in younger and older patients (&lt;55, 55 years) and in patients with smaller and larger (2, &gt;2 cm) tumours (p Z 0.37 and p Z 0.081, respectively); the distribution differed by grade (p &lt; 0.0001) (Fig. <ref type="figure">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Changes in treatment recommendations</head><p><s>Treatment recommendations before and after Recurrence Score testing were available for 527 patients.</s><s>Pretesting, 45.4% were recommended CHT and 54.6% HT (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Overall, 31.9% (95% confidence interval [CI], 27.9e35.9%)</s><s>had a recommendation change posttesting.</s><s>Of the CHT-recommended patients (pretesting), 48.1% (95% CI, 41.8e54.5%)</s><s>were recommended HT post-testing; of the HT-recommended patients (pre-testing), 18.4% (95% CI, 13.9e22.9%)</s><s>were recommended CHT post-testing.</s><s>After knowing the assay results, the proportion of CHT-recommended patients decreased to 33.6% (net reduction: 26%; relative reduction: 38%); the proportion of HTrecommended patients increased to 66.4% (Table <ref type="table" target="#tab_1">2</ref>; p &lt; 0.0001).</s><s>Knowing the assay result impacted treatment recommendations for patients in all Recurrence Score grade, age, and tumour size groups (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Significant changes in the proportion of CHT-and HTrecommended patients were also observed in the low Recurrence Score group as defined in the TAILORx study (&lt;11) <ref type="bibr" target="#b6">[7]</ref> (Table <ref type="table" target="#tab_1">2</ref>).</s><s>These changes were aligned with the Recurrence Score results: a decrease in CHT recommendations was observed in low Recurrence Score patients and an increase in high Recurrence Score patients.</s><s>Upon dividing the intermediate Recurrence  Score group into two subgroups (18e25, 26e30), an increase in CHT recommendation was observed in both subgroups (statistically significant in the former [p Z 0.0094] and trending in the latter [p Z 0.058]) (Table <ref type="table" target="#tab_1">2</ref>).</s><s>The data from the individual studies were similar to those of the pooled analysis with the proportions of patients with a treatment recommendation change ranging from 29.9 to 36.6% (Table <ref type="table" target="#tab_2">3</ref>).</s></p><p><s>The changes in treatment recommendations (an overall decreased CHT and increased HT use) were statistically significant in the French, UK, and German studies (p &lt; 0.0001, p Z 0.020, and p Z 0.047, respectively) and trending (p Z 0.086) in the Spanish study.</s><s>With the exception of the German study, which was characterised by a relatively high proportion of CHT-recommended patients post-testing (41%), the between-study variability in the proportions of CHTand HT-recommended patients decreased post-testing (CHT: from 36.4e52.4% to 25.6e28.7%;</s><s>HT: from 47.6e63.6% to 71.3e74.4%)</s><s>(Fig. <ref type="figure" target="#fig_1">3</ref>).</s></p><p><s>In a univariate analysis, the association between the Recurrence Score category and change in treatment recommendation was significant for both a change from HT to CHT (odds ratio [OR], 30.5 for high Recurrence Score versus intermediate and low categories combined; 95% Wald CI, 6.5e142.6;</s><s>p &lt; 0.0001) and from CHT to HT (OR, 34.0 for low Recurrence Score versus intermediate and high categories combined; 95% Wald CI, 16.6e69.6;</s><s>p &lt; 0.0001).</s></p><p><s>A logistic regression analysis was used to model the probability of changing treatment recommendation as a function of the Recurrence Score category, age (&lt;55, 55 years), tumour size (2, &gt;2 cm), tumour grade (IeIII), PR status (positive, negative), and the interactions thereof, for patients who were initially recommended HT as well as for patients who were initially recommended CHT.</s><s>The probability could not be modelled using all Recurrence Score categories because of the prominent impact of the high and low Recurrence Score results in patients who were initially recommended CHT and HT, respectively.</s><s>Therefore, we combined the intermediate and high categories for the analysis of CHT to HT change and the low and intermediate categories for the analysis of HT to CHT change.</s><s>In a stepwise regression analysis, the interaction of the Recurrence Score category and the other covariates was determined to be non-significant.</s><s>For patients who were initially recommended CHT, having a low (versus high/intermediate) Recurrence Score result was associated with significantly higher odds of CHT to HT change, as was having a grade I or II tumours, being PR-positive, and having smaller tumours.</s><s>For patients who were initially recommended HT, having a high (versus low/intermediate) Recurrence Score result was associated with significantly higher odds of HT to CHT change, as was being younger, having grade III tumours, and being PR-negative (Table <ref type="table" target="#tab_3">4</ref>).</s><s>In a logistic regression analysis using all the aforementioned covariates and Ki-67 levels (which were available only for 241 patients), only the Recurrence Score category was found to be a significant covariate in patients who were initially recommended CHT and none of the covariates were found to be significant in patients who were initially recommended HT.</s></p><p><s>In addition, we evaluated the correlation between Ki-67 and the Recurrence Score results in the 241 patients for whom both values were available and found a moderate Pearson correlation coefficient of 0.46.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">The impact of testing on physicians' confidence regarding treatment recommendations</head><p><s>The four evaluated studies differed in the scale used to assess physicians' confidence regarding treatment recommendations.</s><s>Therefore, these data were not pooled, and the analysis was performed for each study separately.</s><s>Between 33.0% and 60.2% of physicians in the evaluated studies reported increased, 33.0e52.4% reported no change, and 6.8e14.9% reported decreased confidence regarding treatment recommendations (Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>In all studies, knowing the Recurrence Score result was associated with a significant improvement in physicians' confidence regarding treatment recommendations (p &lt; 0.01, all studies).</s><s>Knowing the Recurrence Score result increased the physicians' confidence in the final treatment recommendation, regardless of whether the treatment recommendation changed or not.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>This pooled analysis of four prospective European studies demonstrated that despite differences in therapeutic traditions between countries, Recurrence Score testing significantly impacted adjuvant treatment recommendations and physicians' confidence about treatment recommendations in node-negative ERþ, HER2negative breast cancer, with an overall change rate of 32% and a relative reduction in chemotherapy use of 38%.</s><s>These results are consistent with findings from studies performed worldwide [19e26], all showing a significant impact of testing on adjuvant treatment decisions with a change in approximately one third of patients.</s><s>Treatment recommendations pre-testing were heterogeneous in the different studies with substantial differences in the proportion of patients with low, intermediate, and high Recurrence Score results being recommended chemotherapy.</s><s>Post-testing, the betweenstudy variability decreased and treatment recommendations became more homogeneous, suggesting that broad use of the assay may reduce heterogeneity in treatment decisions.</s><s>Health-economic (HE) studies from all evaluated markets show that broad use of the assay is cost effective (reviewed by Zanotti et al. <ref type="bibr" target="#b26">[27]</ref>).</s><s>Nonetheless, from a medical as well as HE perspective, it is of interest to understand in which patients the assay has the highest utility.</s><s>When assessing treatment recommendation change rates by subgroups, the highest change rate was seen in patients originally recommended chemotherapy (48.1%), grade II (37.3%), and younger patients (40.4%).</s><s>Treatment recommendation changes were seen in a similar range of patients regardless of tumour size (2, &gt;2 cm).</s><s>Thus, it can be argued that from a HE perspective, the most important patient subgroups in which to use the assay include those originally recommended chemotherapy and those with grade II tumours.</s><s>From a medical perspective, it is important to note that all the clinical categories listed above had a clinically relevant treatment  recommendation change rate.</s><s>Therefore, limiting the use of the assay to patients originally recommended chemotherapy means that some patients that could be identified by the assay as having a high likelihood of benefitting from chemotherapy will not receive a treatment that could reduce their distant-recurrence risk.</s></p><p><s>It is sometimes argued that an intermediate Recurrence Score result is unhelpful.</s><s>However, in our study, approximately a third (31.4%) of patients with intermediate results had a treatment recommendation change, demonstrating that intermediate results provide clinically actionable information.</s><s>This is likely related to the fact that the Recurrence Score result is given on a continuous scale.</s><s>Indeed, when the intermediate Recurrence Score group was divided into those with 18e25 and 26e30 Recurrence Score results, CHT recommendation rate increased more pronouncedly in the latter subgroup (relative increase of 37% versus 25%).</s><s>The present data are consistent with studies from the United States and Israel showing that decisions in patients with intermediate results are determined primarily based on whether the result is low or high (within the intermediate range) with a strong increase in chemotherapy recommendations in patients with scores &gt;25 and that other traditional factors such as grade, tumour size, and age also matter <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s>Notably, results from the Clalit study <ref type="bibr" target="#b8">[9]</ref> where patients were not randomized to chemotherapy or no chemotherapy indicate that patients with Recurrence Score results of 25 or less without other high-risk features have little or no benefit from chemotherapy, although it should be noted that the results of TAI-LORx on the role of chemotherapy in intermediate Recurrence Score patients are pending.</s><s>Ki-67 is used in many countries as a marker relevant for treatment decisions despite recent data highlighting substantial issues with reproducibility and data showing that the marker is not predictive of chemotherapy benefit <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b30">31]</ref>.</s><s>In this pooled analysis, many but not all patients had Ki-67 assessments available.</s><s>The correlation between Ki-67 and the Recurrence Score result was modest, consistent with data from the WSG Plan B study <ref type="bibr" target="#b31">[32]</ref>.</s></p><p><s>In conclusion, our findings demonstrate that the Recurrence Score has a substantial impact on treatment recommendations with an overall significant reduction in chemotherapy use.</s><s>The consistency of the results from different countries underlines the utility of the Recurrence Score.</s><s>The highest change rates were seen in patients originally recommended chemotherapy, in younger patients, and in patients with grade II, but there was no subgroup of patients that did not have a clinically relevant rate of change in treatment recommendations.</s><s>Limiting the use of the Recurrence Score assay to the subgroups of patients with the highest change rate may be of HE interest due to cost effectiveness and can even be associated with cost savings.</s><s>From a medical perspective, a broad use of the assay has the advantage of both reducing chemotherapy in those with minimal if any benefit, as well as identifying a smaller proportion of patients that are likely to have a substantial benefit from chemotherapy.</s><s>A broad use of the assay will also reduce the substantial heterogeneity of treatment recommendations currently seen when using traditional markers.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig.1.</s><s>Distribution of Recurrence Score results for the entire cohort (N Z 565).</s><s>Recurrence Score groups were<ref type="bibr" target="#b1">[2]</ref>: blue, Recurrence Score results within the low range (&lt;18); red, Recurrence Score results within the intermediate range (18e30); green, Recurrence Score results within the high range<ref type="bibr" target="#b30">(31)</ref>.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig.3.</s><s>The impact of knowing the Recurrence Score results on treatment recommendations by Recurrence Score category<ref type="bibr" target="#b1">[2]</ref> and study.</s><s>CI, confidence interval; CHT, chemohormonal therapy.</s></p></div></figDesc><graphic coords="7,56.18,498.73,491.49,206.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig. 4. The impact of knowing the Recurrence Score result on physicians' confidence regarding treatment recommendations.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patient and tumour characteristics.</s></p></div></figDesc><table><row><cell></cell><cell>French</cell><cell>Spanish</cell><cell>UK</cell><cell>German</cell><cell>All studies</cell></row><row><cell></cell><cell>study</cell><cell>study</cell><cell>study</cell><cell>study</cell><cell>N Z 565</cell></row><row><cell></cell><cell>n Z 83</cell><cell>n Z 107</cell><cell>n Z 131</cell><cell>n Z 244</cell><cell></cell></row><row><cell>Age, years a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>55 (10)</cell><cell>54 (11)</cell><cell>56 (9)</cell><cell>56 (11)</cell><cell>56 (10)</cell></row><row><cell>Median (range)</cell><cell>55 (33e79)</cell><cell>53 (29e78)</cell><cell>55 (34e72)</cell><cell>56 (25e85)</cell><cell>55 (25e85)</cell></row><row><cell>Age, n (%) b</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;55 years</cell><cell>26 (31.3)</cell><cell>39 (36.4)</cell><cell>29 (22.1)</cell><cell>77 (31.6)</cell><cell>171 (30.3)</cell></row><row><cell>55 years</cell><cell>57 (68.7)</cell><cell>68 (63.6)</cell><cell>102 (77.9)</cell><cell>167 (68.4)</cell><cell>394 (69.7)</cell></row><row><cell>Tumour size, cm c</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>NA</cell><cell>NA</cell><cell>2.0 (1.2)</cell><cell>2.1 (1.2)</cell><cell>2.1 (1.2)</cell></row><row><cell>Median (range)</cell><cell>NA</cell><cell>NA</cell><cell>1.7 (0.5e6.0)</cell><cell>1.8 (0.5e9.0)</cell><cell>1.8 (0.5e9.0)</cell></row><row><cell>Tumour size, n (%) d</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2 cm</cell><cell>67 (80.7)</cell><cell>91 (85.0)</cell><cell>85 (64.9)</cell><cell>154 (63.1)</cell><cell>397 (70.3)</cell></row><row><cell>&gt;2 cm</cell><cell>15 (18.1)</cell><cell>16 (15.0)</cell><cell>46 (35.1)</cell><cell>90 (36.9)</cell><cell>167 (29.6)</cell></row><row><cell>Unknown</cell><cell>1 (1.2)</cell><cell>e</cell><cell>e</cell><cell>e</cell><cell>1 (0.2)</cell></row><row><cell>Tumour grade, n (%) e</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>I</cell><cell>6 (7.2)</cell><cell>37 (34.6)</cell><cell>23 (17.6)</cell><cell>33 (13.5)</cell><cell>99 (17.5)</cell></row><row><cell>II</cell><cell>67 (80.7)</cell><cell>46 (43.0)</cell><cell>86 (65.6)</cell><cell>188 (77.0)</cell><cell>387 (68.5)</cell></row><row><cell>III</cell><cell>10 (12.0)</cell><cell>20 (18.7)</cell><cell>22 (16.8)</cell><cell>23 (9.4)</cell><cell>75 (13.3)</cell></row><row><cell>Unknown</cell><cell>e</cell><cell>4 (3.7)</cell><cell>e</cell><cell>e</cell><cell>4 (0.7)</cell></row><row><cell cols="2">Progesterone receptor status, n (%) f</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>12 (14.5)</cell><cell>16 (15.0)</cell><cell>15 (11.5)</cell><cell>28 (11.5)</cell><cell>71 (12.6)</cell></row><row><cell>Positive</cell><cell>70 (84.3)</cell><cell>90 (84.1)</cell><cell>113 (86.3)</cell><cell>216 (88.5)</cell><cell>489 (86.5)</cell></row><row><cell>Unknown</cell><cell>1 (1.2)</cell><cell>1 (0.9)</cell><cell>3 (2.3)</cell><cell>d</cell><cell>5 (0.9)</cell></row><row><cell>Recurrence Score category, n (%) g</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Low (&lt;18)</cell><cell>47 (56.6)</cell><cell>62 (57.9)</cell><cell>72 (55.0)</cell><cell>131 (53.7)</cell><cell>312 (55.2)</cell></row><row><cell>Intermediate (18e30)</cell><cell>32 (38.6)</cell><cell>35 (32.7)</cell><cell>37 (28.2)</cell><cell>95 (38.9)</cell><cell>199 (35.2)</cell></row><row><cell>High (31)</cell><cell>4 (4.8)</cell><cell>10 (9.3)</cell><cell>22 (16.8)</cell><cell>18 (7.4)</cell><cell>54 (9.6)</cell></row></table><note><p><s>UK, United Kingdom; SD, standard deviation; ANOVA, analysis of variance.a</s><s>p Z 0.44 (ANOVA).b</s><s>p Z 0.099 (chi-squared test).c</s><s>p Z 0.66 (ANOVA).Detailed tumour size information was not available for the French and Spanish studies.d</s><s>p &lt; 0.0001 (chi-squared test).</s><s>e p Z 0.74 (chi-squared test).</s><s>f p Z 0.031 (chi-squared test).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>The impact of knowing the Recurrence Score result on treatment recommendation for the entire cohort, by Recurrence Score category, grades, age groups, and tumour size.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Low Recurrence Score</cell><cell cols="2">Intermediate Recurrence Score</cell><cell cols="2">High Recurrence Score</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(Score values&lt;18)</cell><cell cols="2">(Score values: 18-30)</cell><cell cols="2">(Score values≥31)</cell></row><row><cell></cell><cell>90% 100%</cell><cell>7.0%</cell><cell>10.7%</cell><cell>7.8%</cell><cell>13.8%</cell><cell>24.2% 1.0%</cell><cell>6.2%</cell></row><row><cell></cell><cell>80%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>38.7%</cell></row><row><cell>Propor on of pa ents, %</cell><cell>30% 40% 50% 60% 70%</cell><cell cols="2">57.9% 54.1% 35.1% 35.3%</cell><cell cols="2">55.7% 53.9% 36.5% 32.3%</cell><cell>74.8%</cell><cell>55.3% 38.5%</cell><cell>33.3%</cell></row><row><cell></cell><cell>20%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>10%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>28.0%</cell></row><row><cell></cell><cell>0%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>&lt;55 y</cell><cell>≥ 55y</cell><cell>≤2 cm</cell><cell>&gt;2 cm</cell><cell>Grade I</cell><cell>Grade II</cell><cell>Grade III</cell></row></table><note><p><s>[2].2.Distribution of Recurrence Score categories[2]by patients' age, tumour size, and tumour grade; p Z 0.37, p Z 0.081, and p &lt; 0.0001 for comparing Recurrence Score distribution across age groups, tumour size groups, and grade groups, respectively (chisquared test).</s><s>CHT, chemohormonal therapy; HT, hormonal therapy.</s><s>a p &lt; 0.0001; b p Z 0.0016; c p Z 0.0009; d p Z 0.0094; e p Z 0.058; f p Z 0.0075; g p Z 0.64; h p Z 0.0056; i p Z 0.010.</s><s>All for change from CHT to HT and from HT to CHT; McNemar's test.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>The impact of knowing the Recurrence Score result on treatment recommendation by study.</s></p></div></figDesc><table><row><cell></cell><cell>HT</cell><cell>CHT</cell><cell>Total</cell></row><row><cell></cell><cell>(post-testing)</cell><cell>(post-testing)</cell><cell></cell></row><row><cell cols="2">German study (n Z 244) a</cell><cell></cell><cell></cell></row><row><cell>HT (pre-testing)</cell><cell>99 (40.6%)</cell><cell>28 (11.5%)</cell><cell>127 (52.0%)</cell></row><row><cell>CHT (pre-testing)</cell><cell>45 (18.4%)</cell><cell>72 (29.5%)</cell><cell>117 (48.0%)</cell></row><row><cell>Total</cell><cell>144 (59.0%)</cell><cell>100 (41.0%)</cell><cell>244 (100%)</cell></row><row><cell cols="2">French study (n Z 82) b</cell><cell></cell><cell></cell></row><row><cell>HT (pre-testing)</cell><cell>35 (42.7%)</cell><cell>4 (4.9%)</cell><cell>39 (47.6%)</cell></row><row><cell>CHT (pre-testing)</cell><cell>26 (31.7%)</cell><cell>17 (20.7%)</cell><cell>43 (52.4%)</cell></row><row><cell>Total</cell><cell>61 (74.4%)</cell><cell>21 (25.6%)</cell><cell>82 (100%)</cell></row><row><cell cols="2">Spanish study (n Z 107) c</cell><cell></cell><cell></cell></row><row><cell>HT (pre-testing)</cell><cell>56 (52.3%)</cell><cell>12 (11.2%)</cell><cell>68 (63.6%)</cell></row><row><cell>CHT (pre-testing)</cell><cell>22 (20.6%)</cell><cell>17 (15.9%)</cell><cell>39 (36.4%)</cell></row><row><cell>Total</cell><cell>78 (72.9%)</cell><cell>29 (27.1%)</cell><cell>107 (100%)</cell></row><row><cell>UK study (n Z 94) d</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HT (pre-testing)</cell><cell>45 (47.9%)</cell><cell>9 (9.6%)</cell><cell>54 (57.4%)</cell></row><row><cell>CHT (pre-testing)</cell><cell>22 (23.4%)</cell><cell>18 (19.1%)</cell><cell>40 (42.6%)</cell></row><row><cell>Total</cell><cell>67 (71.3%)</cell><cell>27 (28.7%)</cell><cell>94 (100%)</cell></row><row><cell cols="4">UK, United Kingdom; CHT, chemohormonal therapy; HT, hormonal</cell></row><row><cell>therapy.</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a p Z 0.047; b p &lt; 0.0001; c p Z 0.086; d p Z 0.020.</s><s>All for change from CHT to HT and from HT to CHT; McNemar's test.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Odds ratios for changing treatment recommendations (logistic regression analysis).</s><s>Interactions between the Recurrence Score and the other covariates were found to be non-significant.</s><s>The analysis included 236 patients for the CHT to HT analysis and 286 patients for the CHT to HT analysis (patients with missing data were excluded).</s></p></div></figDesc><table><row><cell>Effect</cell><cell>Odds ratio</cell><cell>95% Wald confidence limits</cell><cell>p-value</cell></row><row><cell>Change from CHT to HT</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Recurrence Score group [2]:</cell><cell>48.5</cell><cell>19.7e119.6</cell><cell>&lt; 0.0001</cell></row><row><cell>low versus int/high (combined)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age: &lt;55 years versus 55 years</cell><cell>0.92</cell><cell>0.40e2.1</cell><cell>0.84</cell></row><row><cell>Tumour size: 2 cm versus &gt;2 cm</cell><cell>2.7</cell><cell>1.1e6.7</cell><cell>0.029</cell></row><row><cell>Tumour grade:</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Grade I versus II</cell><cell>1.4</cell><cell>0.3e6.0</cell><cell>0.64</cell></row><row><cell>Grade I versus III</cell><cell>10.0</cell><cell>1.7e58.0</cell><cell>0.010</cell></row><row><cell>Grade II versus III</cell><cell>7.1</cell><cell>2.2e22.4</cell><cell>0.0008</cell></row><row><cell>PR status: negative versus positive</cell><cell>0.078</cell><cell>0.017e0.36</cell><cell>0.001</cell></row><row><cell>Change from HT to CHT</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Recurrence Score group [2]: high</cell><cell>22.8</cell><cell>4.5e117.0</cell><cell>0.0002</cell></row><row><cell>versus low/intermediate (combined)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age: &lt;55 years versus 55 years</cell><cell>2.3</cell><cell>1.0e5.0</cell><cell>0.042</cell></row><row><cell>Tumour size: 2 cm versus &gt;2 cm</cell><cell>1.4</cell><cell>0.55e3.6</cell><cell>0.48</cell></row><row><cell>Tumour grade:</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Grade I versus II</cell><cell>0.12</cell><cell>0.026e0.51</cell><cell>0.004</cell></row><row><cell>Grade I versus III</cell><cell>0.069</cell><cell>0.011e0.44</cell><cell>0.004</cell></row><row><cell>Grade II versus III</cell><cell>0.60</cell><cell>0.18e2.0</cell><cell>0.41</cell></row><row><cell>PR status: negative versus positive</cell><cell>5.6</cell><cell>2.2e14.4</cell><cell>0.0003</cell></row><row><cell cols="2">CHT, chemohormonal therapy; HT, hormonal therapy; PR, progesterone receptor.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>242) Proportion of physicians, % Confidence decreased after knowing the Recurrence Score result Confidence remained the same after knowing the Recurrence Score result Confidence increased after knowing the Recurrence Score result</head><label></label><figDesc></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J.Albanell  et al. / European Journal of Cancer 66 (2016) 104e113</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>J.A. acknowledges FIS PI12/00680 RD12/0036/0051, 2014SGR740 intensification grant ISCIII, and A Ll. PI12/01421 and RD12/0036/0070.</s></p><p><s>The study sponsor, in collaboration with the investigators, designed the analyses and interpreted the data.</s><s>The authors made the final decision to submit the manuscript for publication.</s><s>All authors contributed to the writing and/or editing of the manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>This work was supported by Genomic Health Inc. Medical writing support was provided by Avital Bareket-Samish, PhD (BioInsight Ltd), and was funded by Genomic Health Inc.</s></p><p><s>Conflict of interest statement J. Albanell, J. Gligorov, S. Holt, J. Blohmer, R. Rouzier, and W. Eiermann declare advisory role for Genomic Health.</s><s>S. Holt received honoraria from Genomic Health.</s><s>C. Svedman is a Genomic Health employee.</s><s>G. Bertelli and A. Lluch declare no conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Paik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="3726" to="e3734" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Paik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cronin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page" from="2817" to="e2826" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Habel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Capra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">R25</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dowsett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cuzick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Mallon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1829" to="e1834" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population</title>
		<author>
			<persName><forename type="first">M</forename><surname>Toi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Iwata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Masuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ohno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nakamura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="3112" to="e3118" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Albain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Barlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Livingston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Yeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="55" to="e65" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Prospective validation of a 21-gene expression assay in breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sparano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Makower</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Albain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Hayes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">21</biblScope>
			<date type="published" when="2015">2015. 2005e14</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Clinical impact of risk classification by central/local grade or luminal like subtype vs. Oncotype DX â : first prospective survival results from the WSG phase III planB trial. Presented at the European Cancer Congress</title>
		<author>
			<persName><forename type="first">O</forename><surname>Gluz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Nitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Kreipe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Christgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Kates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hofmann</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015-09">2015. Sep 25e29, 2015</date>
			<pubPlace>Vienna, Austria</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene Recurrence Score result: 5-year KM estimate for breast cancer specific survival with Recurrence Score results 30 is &gt;98%. Presented at San Antonio Breast Cancer Symposium (SABCS)</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Stemmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Steiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rizel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ben-Baruch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Soussan-Gutman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Geffen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015-12">Dec 8e12, 2015</date>
			<pubPlace>San Antonio, TX</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Breast cancer specific survival in 38,568 patients with node negative hormone receptor positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Presented at San Antonio Breast Cancer Symposium (SABCS)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Petkov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Howlader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gliner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Howe</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015-12">Dec 8e12, 2015</date>
			<pubPlace>San Antonio, TX</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Primary breast cancer: ESMO clinical Practice Guidelines for diagnosis, treatment and followup</title>
		<author>
			<persName><forename type="first">E</forename><surname>Senkus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kyriakides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Penault-Llorca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Poortmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zackrisson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="7" to="e23" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl. 6</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Goldhirsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Winer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Coates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Gelber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Piccart-Gebhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Thurlimann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2206" to="e2223" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
		<ptr target="http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf" />
	</analytic>
	<monogr>
		<title level="j">NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>accessed 31.01.16</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fritsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mennel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Norton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ravdin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Taube</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">33</biblScope>
			<biblScope unit="page" from="5287" to="e312" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Prospective clinical utility study of the use of the 21-gene assay in adjuvant clinical decision making in women with estrogen receptor-positive early invasive breast cancer: results from the SWITCH study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gligorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">B</forename><surname>Pivot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Jacot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Naman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spaeth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Misset</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="873" to="e879" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use</title>
		<author>
			<persName><forename type="first">W</forename><surname>Eiermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rezai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Warm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Friedrichs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="618" to="e624" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ERþ) nodenegative breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Albanell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ruiz-Borrego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alba</forename><forename type="middle">E</forename><surname>Garcia-Saenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Corominas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="625" to="e631" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK</title>
		<author>
			<persName><forename type="first">S</forename><surname>Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bertelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Humphreys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Valentine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Durrani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pudney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2250" to="e2258" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The influence of a gene expression profile on breast cancer decisions</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stojadinovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Swain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Prindiville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cordes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Soballe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="319" to="e323" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Klang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hammerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Liebermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Efrat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Doberne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hornberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="381" to="e387" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Mumby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Norton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rychlik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smerage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1671" to="e1676" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">O</forename><surname>Ademuyiwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>O'connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Edge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Thorat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Sledge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="797" to="e802" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">Australian decision impact study: the impact of oncotype DX recurrence score (RS) on adjuvant treatment decisions in hormone receptor positive (HRþ), node negative (N0) and node positive (Nþ) early stage breast cancer (ESBC) in the multidisciplinary clinic (MDC). Presented at the San Antonio Breast Cancer Symposium (SABCS)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>De Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Speakman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mann</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011-12">Dec 6e10, 2011</date>
			<pubPlace>San Antonio, TX</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Breast medical oncologists&apos; use of standard prognostic factors to predict a 21-gene recurrence score</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Kamal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Loprinzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Dueck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Geiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ingle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1359" to="1e66" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Decision impact and economic evaluation of the 21-gene recurrence score (RS) assay for physicians and patients in Japan</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yamauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yamashige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Takei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yoshida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Suppl. S376)</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The impact of the oncotype Dx breast cancer assay in clinical practice: a systematic review and metaanalysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="e22" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zanotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bottini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Generali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Cappelletti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="8461" to="8e70" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Evaluating utilization characteristics for the oncotype DX recurrence score in early-stage breast cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Patt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Kazzaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shankleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Forsyth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ganesh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>suppl: abstract 625</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Treatment decisions in estrogen receptorpositive early breast cancer patients with intermediate oncotype DX recurrence score results</title>
		<author>
			<persName><forename type="first">G</forename><surname>Fried</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moskovitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Springerplus</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">71</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">An international ki67 reproducibility study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Polley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Hugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Mastropasqua</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="1897" to="e906" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Regan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Mastropasqua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Maffini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Maiorano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Colleoni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="207" to="e212" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB trial. Presented at the San Antonio Breast Cancer Symposium (SABCS)</title>
		<author>
			<persName><forename type="first">O</forename><surname>Gluz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Kreipe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Kates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Christgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Liedtke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shak</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012-12-48">Dec 4e8, 2012</date>
			<pubPlace>San Antonio, TX</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
